Uric Acid Nephropathy Medication
- Author: Mark T Fahlen, MD; Chief Editor: Vecihi Batuman, MD, FACP, FASN more...
The goals of pharmacotherapy are to reduce morbidity and to prevent complications.
Xanthine oxidase inhibitors
Allopurinol is used for the prevention of acute uric acid nephropathy. By blocking the conversion of hypoxanthine and xanthine to uric acid, it produces a reduction in serum uric acid concentration and in the urinary excretion of urates. Allopurinol is used in the treatment of gouty arthritis.[13, 21, 22] Febuxostat may be considered for patients with allopurinol allergy or for those with renal impairment.
Inhibits xanthine oxidase, the enzyme that synthesizes uric acid from hypoxanthine. Reduces synthesis of uric acid without disrupting biosynthesis of vital purines.
Xanthine oxidase inhibitor. Prevents uric acid production and lowers elevated serum uric acid levels. May be considered as an alternative to allopurinol. Febuxostat is extensively metabolized in the liver and excreted in the feces and urine, largely as metabolites. No dosage change is necessary unless severe renal or hepatic impairment exists.
Conger JD. Acute uric acid nephropathy. Med Clin North Am. 1990 Jul. 74(4):859-71. [Medline].
Guest SS. Uric acid and the kidney. Nephrology Rounds 4. Snell Medical Communications; 2001. 1-5.
Dykman D, Simon EE. Hyperuricemia and uric acid nephropathy. Arch Intern Med. 1987 Jul. 147(7):1341-5. [Medline].
Mene P, Punzo G. Uric acid: bystander or culprit in hypertension and progressive renal disease?. J Hypertens. 2008 Nov. 26(11):2085-92. [Medline].
Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015 Sep. 33 (9):1729-41; discussion 1741. [Medline].
Kim Y, Shin S, Kim K, Choi S, Lee K. Effect of Urate Lowering Therapy on Renal Disease Progression in Hyperuricemic Patients with Chronic Kidney Disease. J Rheumatol. 2015 Nov. 42 (11):2143-8. [Medline].
Avram Z, Krishnan E. Hyperuricaemia--where nephrology meets rheumatology. Rheumatology (Oxford). 2008 Jul. 47(7):960-4. [Medline].
Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004 Oct. 44(4):642-50. [Medline].
Kanbay M, Yilmaz MI, Sonmez A, Solak Y, Saglam M, Cakir E, et al. Serum uric acid independently predicts cardiovascular events in advanced nephropathy. Am J Nephrol. 2012. 36(4):324-31. [Medline].
Pea F. Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions. Contrib Nephrol. 2005. 147:35-46. [Medline].
Kim YJ, Kim CH, Sung EJ, Kim SR, Shin HC, Jung WJ. Association of nephrolithiasis with metabolic syndrome and its components. Metabolism. 2013 Jun. 62(6):808-13. [Medline].
Emami-Naini A, Eshraghi A, Shahidi S, Mortazavi M, Seyrafian S, Roomizadeh P, et al. Metabolic evaluation in patients with nephrolithiasis: A report from Isfahan, Iran. Adv Biomed Res. 2012. 1:65. [Medline]. [Full Text].
Roncal-Jimenez C, García-Trabanino R, Barregard L, Lanaspa MA, Wesseling C, Harra T, et al. Heat Stress Nephropathy From Exercise-Induced Uric Acid Crystalluria: A Perspective on Mesoamerican Nephropathy. Am J Kidney Dis. 2015 Oct 5. [Medline].
Bainbridge SA, Deng JS, Roberts JM. Increased xanthine oxidase in the skin of preeclamptic women. Reprod Sci. 2009 Feb 5. [Medline].
Mukherjee E, Mukherji D, Jayawardene SA, et al. Tumor lysis syndrome and acute renal failure--an increasing spectrum of presentations. Clin Nephrol. 2007 Sep. 68(3):186-9. [Medline].
Fagugli RM, Gentile G, Ferrara G, et al. Acute renal and hepatic failure associated with allopurinol treatment. Clin Nephrol. 2008 Dec. 70(6):523-6. [Medline].
Hochberg J, Cairo MS. Rasburicase: future directions in tumor lysis management. Expert Opin Biol Ther. 2008 Oct. 8(10):1595-604. [Medline].
Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008 Oct 23. 359(17):1811-21. [Medline].